{"id":"NCT01005407","sponsor":"Dynavax Technologies Corporation","briefTitle":"Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine","officialTitle":"An Observer-Blinded, Randomized, Parallel-Group, Multi-Center Study Comparing the Safety and Immunogenicity of HEPLISAV™ to Licensed Vaccine (Engerix-B®) Among Healthy Subjects 40 to 70 Years of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-02","primaryCompletion":"2011-01","completion":"2011-05","firstPosted":"2009-11-02","resultsPosted":"2018-01-11","lastUpdate":"2019-03-20"},"enrollment":2452,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Healthy"],"interventions":[{"type":"BIOLOGICAL","name":"HEPLISAV and/or Placebo","otherNames":["Hepatitis B vaccine (recombinant), adjuvanted"]},{"type":"BIOLOGICAL","name":"Engerix-B","otherNames":["Hepatitis B vaccine (recombinant)"]}],"arms":[{"label":"HEPLISAV and/or Placebo","type":"EXPERIMENTAL"},{"label":"Engerix-B(1)","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to evaluate the safety, immunogenicity and lot-to-lot consistency of an investigational hepatitis B virus vaccine, HEPLISAV™, in healthy adults 40 to 70 years of age","primaryOutcome":{"measure":"Percentage of Subjects Who Have a Seroprotective Immune Response","timeFrame":"at Week 12 and at Week 32","effectByArm":[{"arm":"HEPLISAV and Placebo","deltaMin":90.1,"sd":null},{"arm":"Engerix-B","deltaMin":70.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":32,"countries":["United States","Canada"]},"refs":{"pmids":["23727002"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":78,"n":1968},"commonTop":["Nasopharyngitis"]}}